DAEWOONG PHARMACEUTICAL
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial 2025-10-27 19:00
Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform 2025-08-13 15:36
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics 2025-06-11 12:00
CGBIO Receives FDA IDE Approval for NOVOSIS PUTTY, Advancing Toward U.S. Market Entry 2025-04-24 00:00
CG MedTech and CGBIO Showcase Korea's Spine Surgery Excellence to Global Experts 2024-12-31 20:00
Daewoong Pharmaceutical Captivates Global Experts at AMWC-SEA with 'Nabolift,' Redefining Toxin Treatments 2024-12-05 16:33
Daewoong Pharmaceutical Unveils 'Innovative Drug Delivery Technologies' in Milan--From World's First Microneedle Therapy to Once-a-Month Obesity Treatment 2024-10-10 06:16
Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin 2024-07-29 20:00
Novosis Putty Sets the Stage for U.S. Market Success with Promising Clinical Results 2024-05-14 20:00
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA 2023-11-28 08:00
Daewoong Pharmaceutical Initiates Global Export of 'Novel Drug' Launching 'Fexuprazan' in the Philippines 2023-08-16 13:00
Daewoong Pharmaceutical submits a new drug application for Fexuprazan in China challenging the world's largest market for anti-ulcer drugs 2023-07-31 08:00
Daewoong Pharmaceutical has obtained approval for SGLT2i + metformin combination drug Envlomet 2023-07-19 08:52
Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine 2023-05-26 06:00
Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023 2023-05-19 20:00
Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio 2023-04-28 08:58
Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes, in the International SCIE Journal 2023-04-24 14:53
Daewoong Pharmaceutical and Sygnature Discovery announce drug discovery research collaboration 2023-04-18 17:16
Daewoong Pharmaceutical's Envlo to enter the global market in full swing with filing for product license in three ASEAN countries 2023-03-22 21:20
Daewoong Pharmaceutical Reaches Sales of KRW 1.16 Trillion in 2022, Fexuclue Leads The Highest Revenue 2023-02-20 12:29
1 2 3 4